Loading stock data…
NEOG
$8.71+0.10 (+1.10%)
Market OpenUpdated 1:43 PM EDT
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neogen Corporation in the Healthcare sector is trading at $8.71. Wall Street consensus targets $12.00 (3 analysts), implying a +37.8% move over the next 12 months. The stock is currently 24% below its 52-week high of $11.43, remaining 14.0% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 75/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +37.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Sector + growth-aware fair-multiple estimate. Fair P/E = sector-anchor + (ROE × 25) + (max(revenue growth, earnings growth) × 30), capped at 1.6× sector. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. The sector anchor (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) keeps quality compounders from being mechanically penalized against utility multiples. Result is a normalised multiple gauge — not a price target.
Current Price$8.71
Potential Downside
0%
Whystock Fair Value$8.71
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Neogen Corporation develops, manufactures, and markets various products and services for food and animal safety in the United States and internationally. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$2.07B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.97
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-51.94%
Volume
Today's trading volume
878,868
Recent News
Can Neogen Corporation (NEOG) Become One of the Market’s Best Small-Cap Turnarounds?
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
Is Weaker Sales And Returns Reshaping The Investment Case For Neogen’s (NEOG) Valuation Assumptions?
Neogen recently reported that it is contending with falling sales, shrinking returns on capital and EBITDA losses, raising concerns about its operational and financing flexibility. This combination of weaker performance and potential reliance on higher-cost debt calls into question whether the company’s current valuation assumptions remain realistic. We’ll now examine how Neogen’s declining sales and returns on capital reshape its investment narrative and the risk profile investors...
1 of Wall Street’s Favorite Stock to Target This Week and 2 Facing Challenges
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
3 Reasons NEOG is Risky and 1 Stock to Buy Instead
What a fantastic six months it’s been for Neogen. Shares of the company have skyrocketed 53.5%, hitting $9.46. This was partly thanks to its solid quarterly results, and the run-up might have investors contemplating their next move.
5 Must-Read Analyst Questions From Neogen’s Q1 Earnings Call
Neogen’s first quarter results were shaped by contrasting trends across its business lines. Management cited continued core growth in the Food Safety segment, particularly in the United States, while acknowledging significant supplier-driven disruptions in the Animal Safety business. CEO Mikhael Nassif noted, “We encountered several supplier challenges stemming from third-party manufacturers that unfortunately had a meaningful impact on our Animal Safety business.” The company responded by stren